2 news items
Analyst Ratings For Arvinas
ARVN
17 May 24
In the assessment of 12-month price targets, analysts unveil insights for Arvinas, presenting an average target
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCEĀ®)
ARVN
PFE
16 May 24
) is designed to assess the safety, tolerability, and anti-tumor activity of vepdegestrant in combination with palbociclib among 46 patients
- Prev
- 1
- Next